The Impact of Modern Lipid-Lowering and Antihypertensive Therapy on the Remodeling of the Carotid Arteries in Patients with Hypertension

S.M. Koval, L.A. Reznik, K.O. Yushko


The review presents the results of the analysis of literary sources on the possibilities of therapeutic correction of the carotid artery remodeling in hypertensive patients. Data are presented both from clinical studies and prospective multicenter randomized trials on the effect of lipid-lowering and antihypertensive therapy on carotid intima-media thickness and the development of atherosclerosis of carotid arteries. It is shown that the latest generation of statins, calcium antagonists, angiotensin converting enzyme inhibitors and angiotensin receptor type II have the greatest antiremodeling properties.


statins; antihypertensive therapy; intima-media complex; atherosclerosis of the carotid arteries


Bots M.L., Baldassarre D., Simon A., Eric de Groot, O’Leary D.H., Riley W., Kastelein J.J., Grobbee D.E. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? // European Heart Journal. — 2007. — Vol. 28. — P. 398-406. doi: 10.1093/eurheartj/ehl482.

Zanchetti A., Hennig M., Hollweck R., Baurecht H., Bond G., Tang R., Cuspidi C., Parati G., Facchetti R., Mancia G. Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives. Findings in the ELSA // Circulation. — 2009. — Vol. 120(12). — P. 1084-1090. doi: 10.1161/CIRCULATIONAHA.108.773119.

Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis // Circulation. — 2007. — Vol. 115. — P. 459-467. doi: 10.1161/CIRCULATIONAHA.106.628875.

Brohall G., Odén A., Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review // Diabet Med. — 2006. — Vol. 23(6). — P. 609-616. doi: 10.1111/j.1464-5491.2005.01725.x.

Seon C.S., Min K.W., Lee S.Y., Nho K.W., Park S.H., Koo B.K., Han K.A. Cardiovascular Risk Assessment with Vascular Function, Carotid Atherosclerosis and the UKPDS Risk Engine in Korean Patients with Newly Diagnosed Type 2 Diabetes // Diabetes Metab.J. — 2011. — Vol. 35(6). — P. 619-627. doi: 10.4093/dmj.2011.35.6.619.

Espeland M.A., O’Leary D.H., Terry J.G., Morgan T., Evans G., Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors // Current Controlled Trials in Cardiovascular Medicine. — 2005. — Vol. 6(1). — P. 3. doi: 10.1186/1468-6708-6-3.

Spence J.D. Measurement of Intima-media thickness vs. carotid plaque: uses in patient care, genetic research and evaluation of new therapies // International Journal of Stroke. — 2006. — Vol. 1(4). — P. 216-221. doi: 10.1111/j.1747-4949.2006.00068.x.

Furberg C.D., Adams H.P., Applegate W.B. et al. for the ACAPS Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events // Circulation. — 1994. — Vol. 90. — P. 1679-1687. doi: 10.1161/01.CIR.90.4.1679.

Salonen R., Nyyssonen K., Porkkala E. et al. Kuopio Atherosclerosis Prevention Study (KAPS). A populationbased primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries // Circulation. — 1995. — Vol. 92. — P. 1758-1764. doi: 10.1161/01.CIR.92.7.1758.

Mercuri M., Bond M.G., Sirtori C.R. et al. Pravastatin reduces carotid intimamedia thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study // Am. J. Med. — 1996. — Vol. 101(6). — P. 627-634. doi:10.1016/S0002-9343(96)00333-6.

Crouse J.R., Byington R.P., Bond M.G. et al. Pravastatin, lipids and atherosclerosis in carotid arteries (PLACII) // Am. J. Cardiol. — 1995. — Vol. 75. — P. 455-459.

De Groot E., Jukema J.W., Montauban van Swijndregt A.D., Zwinderman A.H., Ackerstaff R.G., van der Steen A.F., Bom N., Lie K.I., Bruschke A.V. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS) // Am. Coll. Cardiol. — 1998. — Vol. 31(7). — P. 1561-1567. doi: 10.1016/S0735-1097(98)00170-3.

Sawayama Y., Shimizu C., Maeda N., Tatsukawa M., Kinukawa N., Koyanagi S., Kashiwagi S., Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST) // J. Am. Coll. Cardiol. — 2002. — Vol. 39(4). — P. 610-616. doi: 10.1016/S0735-1097(01)01783-1.

Smilde T.J., Wissen S., Wollersheim H. et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial // Lancet. — 2001. Vol. 357. — P. 577-581. doi:10.1016/S0140-6736(00)04053-8.

Villines T.C., Stanek E.J., Devine P.J., Turco M., Miller M., Weissman N.J., Griffen L., Taylor A.J. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration // J. Am. Coll. Cardiol. — 2010. — Vol. 55(24). — P. 2721-2726. doi: 10.1016/j.jacc.2010.03.017.

Beishuizen E.D., van de Ree M.A., Jukema J.W., Tamsma J.T., van der Vijver J.C., Meinders A.E., Putter H., Huisman M.V. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease // Diabetes Care. — 2004. — Vol. 27(12). — P. 2887-2892. doi: 10.2337/diacare.27.12.2887.

Ridker P.M., Macfadyen J.G., Nordestgaard B.G., Koenig W., Kastelein J.J., Genest J., Glynn R.J. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5 % to 10 % and 10 % to 20 % 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for «intermediate risk» // Circ. Cardiovasc. Qual. Outcomes. — 2010. — Vol. 3(5). — P. 447-452. doi: 10.1161/CIRCOUTCOMES.110.938118.

Nissen S.E., Nicholls S.J., Sipahi I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial // JAMA. — 2006. — Vol. 295. — P. 1556–1565. doi:10.1001/jama.295.13.jpc60002.

Hong Y.J., Jeong M.H., Hachinohe D. et al. Comparison of Effects of Rosuvastatin and Atorvastatin on Plaque Regression in Korean Patients With Untreated Intermediate Coronary Stenosis // Circ. J. — 2011. — Vol. 75. — P. 398-406. doi: 10.1253/circj.CJ-10-0658.

Soeda T., Uemura S., Okayama S. et al. Intensive Lipid-Lowering Therapy With Rosuvastatin Stabilizes Lipid-Rich Coronary Plaques (Evaluation Using Dual–Source Computed Tomography) // Circ. J. — 2011. — Vol. 75. — P. 2621-2627. doi:10.1253/circj.CJ-11-0139.

Crouse J.R., Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O’Leary D.H., Grobbee D.E., Bots M.L. for the METEOR Study Group. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis: the METEOR Trial // JAMA. — 2007. Vol. 297(12). — P. 1344-1353. doi:10.1001/jama.297.12.1344.

Underhill H.R., Yuan C., Zhao X.Q. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial // Am. Heart J. — 2008. — Vol. 155(3). — P. 584.e1-8. doi: 10.1016/j.ahj.2007.11.018.

Nohara R., Daida H., Hata M., Kaku K., Kawamori R., Kishimoto J., Kurabayashi M., Masuda I., Sakuma I., Yamazaki T., Yokoi H., Yoshida M. Justification for Atherosclerosis Regression Treatment (JART) Investigators. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study // Circ. J. — 2012. — Vol. 76(1). — P. 221-229. doi:10.1253/circj.CJ-11-0887

Dahlof B., Sever P.S., Poulter N.R., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. — 2005. — Vol. 366. — P. 895-906. doi:10.1016/S0140-6736(05)67185-1.

Wang J.G., Staessen J.A., Li Y. et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials // Stroke. — 2006. — Vol. 37. — P. 1933-1940. doi:10.1161/01.STR.0000227223.90239.13

Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) // Circulation. — 2001 — Vol. 103(13). — P. 1721-1726. doi: 10.1161/01.CIR.103.13.1721.

Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. // Circulation. — 2000. — Vol. 102. — P. 1503-1510. doi: 10.1161/01.CIR.102.13.1503.

Zanchetti A., Bond M.G., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial // Circulation. — 2002. — Vol. 106. — P. 2422-2427. doi: 10.1161/01.CIR.0000039288.86470.DD

Brown M.J., Palmer C.R., Castaigne A. et al. Principal results from the international nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT) // Eur. Heart J. Suppl. — 2001. — Suppl. B. — B20-B26. doi: 10.1016/S1520-765X(01)90053-7

Simon A., Gariepy J., Moyse D. et al. Differential effect of nifedipine and co-amilozide on the progression of early carotid wall changes // Circulation. — 2001. — 103. — 2949-2954. doi: 10.1161/01.CIR.103.24.2949.

Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) // Circulation. — 2001. — Vol. 103(7). — P. 919-925. doi: 10.1161/01.CIR.103.7.919.

Ono H., Minatoguchi S., Watanabe K., Yamada Y., Mizukusa T., Kawasaki H., Takahashi H., Uno T., Tsukamoto T., Hiei K., Fujiwara H. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension // Hypertens. Res. — 2008. — Vol. 31(2). — P. 271-279. doi: 10.1291/hypres.31.271.

Napoli C., Bruzzese G., Ignarro L.J., Crimi E., de Nigris F., Williams-Ignarro S., Libardi S., Sommese L., Fiorito C., Mancini F.P., Cacciatore F., Liguori A. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension // Am. Heart J. — 2008. — Vol. 156(6) — P. 1154.e1-8. doi: 10.1016/j.ahj.2008.09.006.

Sonoda M., Aoyagi T., Takenaka K. et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors) // Int. Heart. J. — 2008. — Vol. 49, № 1. — P. 95-103. doi:10.1536/ihj.49.95

Baguet J., Asmar R., Valensi P. et al. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study // Vasc. Health Risk Manag. — 2009. — Vol. 5(1). — P. 175-183. doi:10.2147/VHRM.S3409.

Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients // J. Hum. Hypertens. — 2006. — Vol. 20(10). — P. 787-794. doi:10.1038/sj.jhh.1002067.

Zanchetti A., Crepaldi G., Bond M.G., Gallus G., Veglia F., Mancia G., Ventura A., Baggio G., Sampieri L., Rubba P., Sperti G., Magni A. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial // Stroke. — 2004. — Vol. 35(12). — P. 2807-2812. doi: 10.1161/01.STR.0000147041.00840.59.

Ludwig M., Stapff M., Ribeiro A., Fritschka E., Tholl U., Smith R.D., Stumpe K.O. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study // Clin.Ther. — 2002. — Vol. 24(7). — P. 1175-1193.

Mörtsell D., Malmqvist K., Held C., Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study // J. Intern.Med. — 2007. — Vol. 261(5). — P. 472-479. doi: 10.1111/j.1365-2796.2007.01775.x

Ariff B., Zambanini A., Vamadeva S., Barratt D., Xu Y., Sever P., Stanton A., Hughes A., Thom S. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension // Stroke. — 2006. — Vol. 37(9). — P. 2381-2384. doi: 10.1161/01.STR.0000236839.69658.c5

Hirohata A., Yamamoto K., Miyoshi T. et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of Olmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial // J. Am. Coll. Cardiol. — 2010. — Vol. 55(10) — P. 976-982. doi: 10.1016/j.jacc.2009.09.062.

Stumpe K.O., Agabiti-Rosei E., Zielinski T., Schremmer D., Scholze J., Laeis P., Schwandt P., Ludwig M. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study // Ther. Adv. Cardiovasc. Dis. — 2007. — Vol. 1(2). — P. 197-106. doi: 10.1177/1753944707085982.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта